Key Drivers
- Strong liquidity
- Margin compression
- Low leverage
AIAI Summary
INMD is now better viewed as a cash-rich, low-debt medical-device name with downside support from activist/takeover optionality, but until revenue re-accelerates and margins stabilize, it remains a neutral, catalyst-driven turnaround rather than a growth compounder.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Margin compression
- •Low leverage
INMD remains financially strong and undervalued on cash and earnings, but recent quarter margin compression and heavy operating खर्चs warrant close monitoring of expense control and revenue consistency.
Price Behavior
Key Price Behavior Insights:
- •Support Holding
- •Lower Highs
- •Failed Breakout
Over the last month, INMD has drifted sideways to lower with orderly selling, repeated support near $15.09-$15.10, and failed rebounds below $15.31-$15.37, leaving the setup neutral and best suited to waiting for a decisive breakout or breakdown.
Orderly pullback with repeated rebounds that stalled below resistance and did not break out
Sentiment & News
Key News Insights:
- •Stable revenue
- •Board scrutiny
- •Compensation tension
InMode posted stable Q2 2026 revenue of $95.6M while facing shareholder pressure over board re-election and compensation proposals.
The shares may remain under governance-related pressure despite unchanged revenue performance
Similar Companies in Healthcare
Other companies in the same sector with AI ratings